We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

By LabMedica International staff writers
Posted on 20 Sep 2023
Print article
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in the European Union (EU) market.

Tasso, Inc.’s (Seattle, WA, USA) Tasso+ device is intended for single-use and is capable of obtaining microliter amounts of capillary whole blood. What sets Tasso+ apart is its virtually pain-free and user-friendly design, along with groundbreaking technology, which enhances user satisfaction. This makes it ideal for remote blood collection, particularly in decentralized clinical trials run by pharmaceutical companies, focusing on pharmacokinetic and biomarker research.

Tasso+ offers a patient-friendly approach to blood collection that helps break down access barriers, allowing patient groups who are typically underserved or understudied to take part in clinical trials. Beyond research, healthcare providers can also use the device to assess blood chemistries, thus expanding care accessibility. The device had previously received Class II 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2022. With the new CE Mark, Tasso+ has become the first device in its category to get full clearance both in the U.S. and the EU.

“This designation is an important milestone for Tasso, allowing us to build upon the success of our CE Marked Tasso-M20 device and continue to expand our commercial footprint and reduce healthcare access barriers in Europe, where demand increasingly grows for patient-centric solutions,” said Ben Casavant, PhD, CEO and co-founder of Tasso. “The Tasso+ CE Mark enables us to support the pharmaceutical industry, academic and government institutions on research and clinical initiatives, as well as accelerate access to remote testing and care for more patient populations. We are excited to expand our customer base in Europe.”

Related Links:
Tasso, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.